

REFERENCES

- Ahmed N, Thorley R and Xia D et al.:** Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. *Am J Respir Crit Care Med* 1996; 153: 1141-7.
- Allair AD, Ballenge KA and Wells SR:** Placental apoptosis in preeclampsia. *Obstet Gynecol* 2000; 96: 271.
- American College of Obstetricians and Gynecologists (ACOG) Practice bulletin:** Diagnosis and management of preeclampsia and eclampsia. *Obstet Gynecol*. 2002;99(1):159–167.
- American College of Obstetricians and Gynecologists Committee on Obstetric Practice:** Diagnosis and management of preeclampsia. *Int J Gynecol Obstet* 2002; 77: 67-75 (ACOG Practice Bulletin).
- Aquilma J, Barnett A and Thompson, O et al.:** Second trimester maternal serum inhibin. A concentration as an early marker for preeclampsia. *Am J Obstet Gynecol* 1999; 181: 131.
- Arias F:** Prolonged pregnancy. In: *Practical Guide to High-Risk Pregnancy and Delivery*. 2nd ed. Mosby Yearbook Inc. St. Louis, Baltimore, Boston 1993; 150-161.
- Bainbridge SA, Sidle, EH and Smith GN et al.:** Direct placental effect of cigarette smoking protect women from preeclampsia in the specific roles of carbon monoxide and antioxidant systems in the placenta. *Med Hypotheses* 2005; 64: 17.
- Ballows SP, Kushner I:** C-reactive protein and the acute phase response. *Adv Intern Med* 37: 313, 1992.

- =====
- Bardeguéz AD, McNerney R, Frieri M, Verma UL, and Tejani N:** Cellular immunity in preeclampsia: alterations in T lymphocyte subpopulations during early pregnancy. *Obstet Gynecol*; 1991; 77: 859-62.
- Batashki L, Milcher N and Topolvska D .2006.** C-reactive protein in women with preeclampsia. *Akush Ginekol (Sofia)*; 45(Suppl. 1): 47-50.
- Belfort MA, Saade GR, Grunewald C, Dildy GA, Abedejos P and Herd JA, Nisell H:** Associates of cerebral perfusion pressure **with** headache in women with preeclampsia. *Br. J. Obstet Gynecol*; 106(8): 814-21.
- Belizan JM, Villar J.** the relationship between calicium intake and edema-proteinuria and hypertension gestosis. An hypothesis. *American Journal of Clinical Nutrition* 1980; 33: 2202.
- Belo Hang HS, Kwan JY and Kim MA et al.:** Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. *Int J Gyencol Obstet* 2007; 92(2): 105-109.
- Belo L, Santos-Silva A, Rocha S, Caslake M, Conney J, Pereira Leite L, et al.:** Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. *Eur J Obstet Gyencol Reprod Biol* 2005; 123: 46-51.
- Blackbrn CA, Keelan JA and Taylor RS et al.:** Two-stage elevation of cell free feta DNA in maternal sera before onset of preeclampsia. *Am J Obstet Gyencol* 2004; 190: 707.

- =====
- Bolte AC, Van Geijn HP, Deker GA:** Management and monitoring of severe preeclampsia. *Eur J Obstet Gyencol Reprod Biol* 2001; 96(1): 8.
- Borghi C, Esposti DD, Immordino V, et al.:** Relationship of systemic haemodynamics, left ventricular structure and function, and plasma naturetic peptide concentration during pregnancy complicated by preeclampsia. *Am J Obstet Gyencol* 2000; 183: 140.
- Bosio PM, Wheeler T and Anthong F et al.:** Maternal plasma vascular endothelial growth factor concentration in normal and hypertensive pregnancies. *Am J Obstet Gyencol* 2001; 174: 146.
- Boston JL, Beauchene RE, Guinkshank DP.** Erythrocyte and plasma magnesium during teenage pregnancy: Relationship with blood pressure and pregnancy induced hypertension. *Obstetrics and Gynaecology* 1989; 73: 169-174.
- Brown CEL, Purdy PD and Cunningham FG (1988):** Head computed tomographic scans in women with eclampsia. *Am J Obstet Gynecol* 159: 915.
- Brown DW, Dueker N, Jamieson DJ, Cole JW, Wozniak MA, Stern BJ, Giles WH and Kittner SJ:** Preeclampsia and the risk of ischemia stroke among young women. Results from the strock. Prevention in young women study 2006.
- Buchbinder A, Sibai BM, Caritis S et al.:** Adverse perinatal outcomes are significantly higher in sever gestational hypertension than in mild preeclampsia. *Am J Obstet Gyencol* 2002; 186: 66.

- =====
- Cahill AG, Macones GA, Odibo AO, Stamilio DM.** Magnesium for seizure prophylaxis in patients with mild preeclampsia. *Obstet Gynecol.* 2007;110(3):601–607.
- Carroli G, Duly L, Belizan JM, Villar J.** Calcium supplements during pregnancy – a systematic review of randomized controlled trials. *British Journal of Obstetrics and Gynaecology* 1994; 101: 753-758.
- Cermak J, Key NS and Bach RR et al.:** C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood* 1993; 82: 513-20.
- Chambers KA and Cain TW:** Post partum blindness. Two Cases. *Ann Emerg Med* 2004; 43: 243.
- Chammas MF, Nguyen TM, Li MA, et al.** Expectant management of severe preeclampsia: Is intrauterine growth restriction an indication for immediate delivery? *Am J Obstet Gynecol.* 2000;183 (4):853–858.
- Chappell L. Bewleys:** Preeclamptic toxemia: The role of uterine artery Doppler *Br J Obstet Gyencol* 1998; 105: 379.
- Chappell LC, Seed PT, Briley A et al.:** A longitudinal study of biochemical variables in women at risk of preeclampsia. *Am J Obstet Gyencol* 2002; 187: 127.
- Chavarria ME, Lara-Gonzalez-Gleason A, et al.:** Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. *Am J Obstet Gyencol* 2003; 188: 986.

- =====
- Chipchuse J, Peebles D and Rodeck C:** Severe preeclampsia and cerebral blood volume response to postural change. *Obstet Gynecol* 2003; 101: 86-92.
- Conde-agudelu A, Belizan JM:** Risk factor for pre-eclampsia in a large cohort of Latin American and Caribbean women. *Br. J. Obstetric Gyencol* 2004; 107: 75.
- Cunningham F, Kenneth J, Steven LB, John CH, Larry CG, Katharine DW:** Hypertensive disorder in pregnancy, From *Williams Obstetric*, 22nd edition, 2005, P: 764.
- Cunningham FG Lindhermer MD:** Hypertension in pregnancy (see comments) *N Engl J Med* 1992; 236: 927.
- Cunningham G, Gant NF and Leveno KJ et al.:** Hypertensive disorder in pregnancy, common complication of pregnancy. In: Andrea S, Susen R, Noujaim and Karen D (eds): *Williams Obstetrics* 21st edition McGraw-Hill 2001; 568-618.
- Dekker G and Sibai:** Primary, secondary and tertiary prevention of preeclampsia-*Lancet* 2001; 357: 209-215.
- Dekker GS, Sibai BM,** Early detection of pre-eclampsia. *American Journal of Obatetrics and Gynecology*, 1991; 165:160-172.
- Delia M, Paternoster, Sara Fantinato Andreostella, Kimta Naradoumbe Nanhorngue et al.:** C-reactive protein in hypertensive disorder in pregnancy 2008.
- Department of health.** Report on Confidentiality Enquiries into Maternal Deaths in the UK. 1988- 90. London: DoH,1994: 22-33.

- =====
- Dowling et al.:** Immune events in demyelinating disease. In Wolfgang, F., Ellism GW et al.: Multiple sclerosis. Academic Press Inc. New York, 269-277, 1972.
- DRG CRP, HS:** High sensitivity enzyme immunoassay for the quantitative determination of –CR reactive protein concentration in human serum. 2005; 1: 11: 11-11.
- Editorial.** Bed rest and non-proteinuric hypertention in pregnancy. Lancet 1992; 339: 1023-1024.
- Eklom E:** Hemodynamic measures in prediction of preeclampsia: Acla Obstet Gyencol Scand 1997; 164(76): 101.
- Ernest E, Hammerschmidt DE, Bagge U, Matria A, Dormandy JA:** Leukocytes and the risk of ischemic diseases. JAMA, 2000; 257 (17): 2318.
- Estelles A, Gilabert J Grancha S et al.:** Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in sever preeclampsia. Thromb Haemost. 1998; 79: 5000.
- Ferris TR:** Prostanoids in normal and hypertensive pregnancy. Hypertension in pregnancy handbook of hypertension. Amsterdam: El-Servier, 1988; 10: 102.
- Festa A, D'Agostino R Jr, Howard G et al.:** Chronic sub clinical inflammation as part of the insulin Resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 183: 853.
- Friedman SA, Lindheimer MD:** prediction and differential diagnosis. In: Lindheimer MD. Roberts JM, Cunningham FG eds); Shesley's hypertensive disorders in pregnancy 2nd ed. Stm-Ford CT. Appleton and Lange 1999; P: 201.

- =====
- Friedman SA: Schiff E, Kao L, Sibai BM:** Neonatal outcome
Gynecol 1995; 172: 1785.
- Gambling DR. Hypertensive disorders.** In: Chestnut DH, editor.
Obstetric Anesthesia. 3rd ed. Philadelphia, PA: Elsevier Mosby;
2004.
- Ganut G and Ramin K:** Immunological Tolerance of the human
fetus. Am J Perinatol 2001; 18(6): 299.
- Garvic VO:** Hypertension in pregnancy: Diagnosis and treatment.
Mayo Clin Proc 2000; 75 1071-1076 (Level III).
- Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon
BH, Maymon E and Romero R:** Phenotypic and metabolic
characteristics of monocytes and granulocytes in
preeclampsia. Am J Obstet Gynecol 2001; 185: 792-7.
- Gifford RW, August PA and Canningham G:** Report of the
national high blood pressure education program working
group on high blood pressure in pregnancy. Am J Obstet
Gynecol 2000; 183: 5-22.
- Granger, JP, Alexander, BT, Benett WA, Khaht RA:**
Pathophysiology of pregnancy-included hypertension. Am J
Hypertension 2001; 14: 1785.
- Greer A:** Haemostasis and thrombosis in pregnancy in: Haemostasis
and thrombosis in obstetrics and Gynecology. Bloom Al,
Forbes CD, Thomas DP, Tuddenham EGD, eds. 3rd
Edinburgh Churchill Livingstone 1994; 987-3.
- Grunewald C:** Biochemical prediction of preeclampsia: Acla
Obstet Gynecol Scand 1997; 164: 76.

- =====
- Haddad B, Deis S, Goffinet F, et al.** Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. *Am J Obstet Gynecol*. 2004;190(6): 1590–1595.
- Haddad B, Desuau D and Jeffrey C et al.:** Serum B2-micoglobulin level as an early marker of preeclampsia. *Am J Obstet Gynecol* 2001; 182: 595.
- Halligan A, Bonnar J, Shappard B, et al.:** Haemostatic, Fibrinolytic, and endothelial variables in normal pregnancies and preeclampsia. *Br J Obstet Gynecol* 1994; 101: 488.
- Hanssens M, Kierse MJNC, Vankelcom F, Van Assche FA.** **Fetal and** neonatal effects of treatment with angiotensin converting enzymes inhibitors in pregnancy. *Obstetrics and Gynecology* 1991; 78: 128-135.
- Harlow FH, Brown MA, Brighon TA, et al.:** Platelet activation in the hypertensive disorder of pregnancy. *Am J Obstet Gynecol* 2002; 187: 688.
- Hayashi M, Hamada Y, and Ohkura T:** Elevation of granulocyte macrophage colony stimulating factor in the placenta and blood in preeclampsia. *Am J Obstet Gynecol* 2004; 190: 456.
- Heikkinen J, Mottonen M, Komi J, Alanen A and Lassila O:** Phenotypic characterization of human decidual macrophages. *Clin Exp Immunol* 2003; 131: 498-505.
- Hertig AT:** Vascular pathology in the hypertensive albuminuric toxemias of pregnancy. *Clinics*; 4: 1945; 602. Quoted from: Cunningham FG Gant NE, Leveno KJ, Steven L Bloom, John C Houth, Larry C. Glistrap III, and Katharine D

- =====
- Wenstorm (2005): Hypertensive disorders in pregnancy. In Williams Obstetrics, 22nd ed., New York, McGraw-Hill; p. 761-808.
- Hind CRH and Pepys MB:** The role of serum C-reactive CRP measurement in clinical practice. *Int Med* 1984; 5: 112-151.
- Hiroko M:** Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. *J Clin Endocrin Metab* 1998; 83(9): 3225-3229.
- Holzgrev W, Steinbor CL and Kulz T et al.:** Elevation in erythroblast count in maternal blood before the onset of preeclampsia. *Am J Obstet gynecol* 2001; 184: 165.
- Hu X, Ye R and Yang Z:** The clinical study on urinary albumin and calcium output in 24 hours to serve as early markers for pregnancy induced hypertension *Zhonghua Fu Chan Ke Zhi* 1999; 34(12): 709.
- Huilson GB, Ihorsen P, Jeune B and Bakketeig LS:** C-reactive protein: Aserological marker for preterm delivery *Acta Obstet Gyencol Scand* 2002; 81: 424-429.
- Imperiale TF, Petrulis AS,** A meta-analysis of low dose aspirin for the prevention of pregnancy induced hypertensive disease. *Journal of the American Medical Association* 1991; 266: 260-265.
- Jackson DW, Sciscione A and Hartly TL et al.:** Lysosomal enzymuria in preeclampsia. *Am J kidney Dis* 1996; 27(6): 826.
- Janeway CA, Travers P and Walport M et al.:** Immunobiology: the immunosystem in health and disease. New York. NY: Garland Publishing; 2001; 21-52.

- =====
- Jay DI, Waits KB:** Clinical applications of C-reactive protein in pediatrics. *Pediatr Infect Dis J* 1997; 16: 735.
- Jialal T, Devaraj S and Venugopal SK:** Hypertension 2004; 44: 6.
- John JH, Ziebland S, Yudkin P, Roe LS and Neil HA (2002):** Effects of fruit and vegetable consumption on plasma antioxidant concentration and blood pressure: A randomized controlled trial. *Lancet* 2002; 359: 1969-74.
- Katz VL, Richard T and Moodle J:** Preeclampsia into eclampsia: Toward a new paradigm. *J Obstet Gynecol* 2000; 182: 1389.
- Keelan JA, Taylor R, Schellenberg JC et al.:** Serum activin A, Inhibin A, and Folistatin concentration in preeclampsia of small for gestational age pregnancies. *Obstet Gynecol* 2002; 99: 267.
- Khedun SM, Naicker T and Moddley J:** Tissue Kallikrein activity in pregnancy. *Aust NZJ Obstet Gynecol* 2000; 40(4): 451.
- Kim YI, Williamson RA and Murray JC:** Genetic susceptibility to preeclampsia. *Am J Obstet Gynecol* 2001; 184: 1211.
- Kluft C and de Maat MPM:** Sensitive markers of inflammation make it possible to study the chronic process: The rise of interest in low levels of C-reactive protein. *Vasc Pharmacol* 2002; 39: 99-104.
- Konijnenberg A, Slokkers EW and Jaris AM et al.:** Extensive platelet activation in preeclampsia compared with normal pregnancy. *Am J Obstet Gynecol* 1997; 176: 461.
- Kumru S, Aydin S, Gursu MF, Ozacan Z:** Changes of serum paraoxonase (an HDL-cholesterol-associated Lipophilic

- antioxidant) and arylesterase activities in sever preeclamptic women. Eur J Obstet Gyencol Reprod Bio 2004; 2: 177-81.
- Kushner I, Jiang SL, Zhang D, Lozanski G and Samols D:** Ann NX Acad Sci 1995; 762: 102.
- Lang RM, Pridjian G, Feldman T et al.:** Left Ventricular Mechanisms in Preeclampsia. Am Heart J, 1991; 121: 1768.
- Less C, Parra M, Missfelder-Lobos H et al.:** Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks. Obstet Gyencol 2001; 98(3): 369.
- Levin AC, Doering PL, Hutton RC.** Use of nifedipine in the hypertensive dieases of pregnancy. Annals of Pharmacotherapy 1994; 28: 1371-1378.
- Levine KJ, Qian C and Leshane ES et al. (2004):** Two stage elevation of cell free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 190: 707.
- Li YH, Chen JH and Tsai WC et al.:** Synergistic effect of thrombodulin promoter-33 G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Hemost 2002; 87(1): 86.
- Lindheimer MD, Taler SJ, Cunningham FG.** Hypertension in pregnancy. J Am Soc Hypertens. 2008;2(6):484–494.
- Lindow SW, Davies N, Davey DA, Smith JA.** The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. British Jounal of Obstetrics and Gynaecology1988; 95: 1276-1281.
- Livingstone JC, Chin R, Haddad B et al.:** Reduction of vascular endothelial growth factor and placental growth factor

- concentration in sever preeclampsia. Am J Obstet Gyencol 2000; 183: 554.
- Lorentzon B, Endreson MJ and Clausen T et al.:** Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertension in pregnancy 1994; 103: 74-79.
- Loukovaara MJ, Alfthan HV, Kurki MT, Hiilesmaa VK, Andersson SHM:** Serum highly sensitive C-reactive protein in preterm premature rupture of membranes. Eur J Obstet Gyencol Reprod Biol 2003; 110: 26-8.
- Lusis AJ:** Atherosclerosis. Nature, 2000; 407(681): 233.
- Ma S, Bai S and Bian X:** Study on thrombomodulin and plasminogen activator inhibitor type-1 in Patients of pregnancy induced hypertesnion. Zhongua. Fu. Chan Ke. Az. Zhi 1999; 34(12): 712.
- Malee MP, Make KM and Azuma SD et al.:** Increase in plasma atrial natriuretic peptide concentration anledate clinical evidence of patient preeclampsia, J Clinical Endocrinol 1992; 133: 1266.
- Managing high blood pressure.** Drugs and Therapeutics Bulletin 1993; 31 (14): 53-56.
- Manten GT, Vander Hoek YY, Marko Sikkema J, Voorbig HA, Hameeteman TM, Visser GH, and Franx A:** The role of lipoprotein (a) in complicated by preeclampsia. Med Hypothesis; 2005; 64: 162-9.
- Mass J, Forest JC and Moutquin JM (1993):** A prospective study of several potential biologic markers for early prediction of

- development of preeclampsia. Am J Obstet Gynecol 1993; 169: 501.
- Matter F and Sibai BM:** Eclampsia: Risk factor for maternal morbidity. J Obstet Gynecol 2000; 182: 307.
- McCall:** Cerebral circulation and metabolism in toxemia of pregnancy: observations on the effects of veratrum viride and a presolin (1-hydrazinophthalazine). Am J Obstet Gynecol 1953; 66: 1015-1030. Quoted from: David K James, Philip J Steer, Carl PW Weiner, and Benard Gonik, hypertension in high risk pregnancy: management options 3rd ed., USA, El Sevier; p. 772-797.
- Millar TGB, Carpell SK and Albano JDM:** Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample. Br J Obstet Gynecol 1996; 103: 421-426.
- Moran P, Lindheimer MD, Davison, JM:** The renal response to preeclampsia. Semin Nephrol 2004; 24: 588.
- Moretti M, Phillips M, Abouzeid A et al.:** increased breath markers of Oxidative stress in normal pregnancy and in preeclampsia. Am J Obstet Gynecol 2004; 190: 1184.
- Moseman CP and Shelton S:** Permanent blindness as a complication of pregnancy induced hypertension. Obstet Gynecol 2002; 100 :943.
- Naden RP, Redman CWG.** Antihypertensive drugs in pregnancy. Clinics in Perinatology 1985; 12 (3): 521-538.
- National High Blood Pressure Education Program Working Group On high Blood Pressure in Pregnancy:** Report of

- =====
- The National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
- Nishikawa S, Miyamoto A, Yamamoto H et al.:** Preeclamptic serum enhances endothelial converting enzyme expression in cultured endothelial cell. Am J hypertens 2001; 14(1): 77.
- Noris M, Todeschini M, Cassis P et al.:** L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species hypertension 2004; 43: 614.
- Odegard RA, Vatten LJ and Nilsen et al.:** Preeclampsia with fetal growth Obstet Gynecol 2000; 96: 950.
- Page NM, Woods RJ, Gardiner SM et al.:** Excessive placental secretion of neurokinin B during the Third trimester causes pre-eclampsia. Nature 2000; 405: 791.
- Pasceria V, Willerson JT, Yeh ETH:** Direct proinflammatory effect of C-reactive protein on human endothelial cell circulation, 2000; 102(18): 2165.
- Paternoster DM, Fantinato S, Stella A:** C-reactive protein in hypertensive disorders in pregnancy Clin Appl Thromb Hemost 2006; 12(3): 330-7.
- Pearson TA, Mensah GA and Alexander RW et al.:** Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for health care professionals from the centers for disease control and prevention and the American Heart Association Circulation, 2003; 107: 499-511.

- =====
- Petroff MG, Sedlmayr P, Azzola D and Hunt JS:** Desidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. *J Reprod Immunol* 56: 3-17.
- Phocas I, Rizos D and Papoulias J et al.:** A comparative study of serum soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 in preeclampsia. *J Perinatal* 2001; 20(2): 114.
- Powers RW, Dunbar MS and Gallaher MJ et al.:** The 677 CT methylene tetrahydrofolate reductase mutation pregnancy. *Obstet Gyencol* 2003; 101: 762.
- Predhan AD, Manson JE, Rifai N, Buring JE, Ridker PM:** C-reactive protein, Interleukin 6 and risk of developing type 2 diabetes mellitus. *JAMA* 2001; 286: 327-34.
- Qiu C, Luthy DA, Zhang C, Walsh SW, Lesisnring WM, Willtiams MA:** Prospective study of maternal serum C-reactive protein concentrations and risk of preeclamsia. *Am J Hypertens* 2004; 17: 154-60.
- Rangel-Fruasto SM Oittet D, Costigan M, Hwang T, Davis CS, Wenzel RP:** The natural of the systemic inflammatory response (SIRS), A prospective study, *JAMA* 1995; 273: 117-23.
- Rebelo I, Carvalho-Guerra F, Pereira-Leite L and Quintanilh A:** Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancy. *Eur J Obstet Gynecol Reprod* 1995; 14: 2386-2391.

- =====
- Redman CW, Sacks GP, Sargent IL:** Preeclampsia an excessive maternal inflammatory response to pregnancy. *Am J Obstet Gynecol* 1999; 180: 499-506.
- Redman CW, Sacks GP, Sargent IL:** Preeclampsia an excessive maternal inflammatory response to pregnancy. *Am J Obstet gyencol* 1999; 180: 499-506.
- Redman CWG, and Sargent IL:** Preeclampsia, the placenta, and the maternal systemic inflammatory response: a review. *Placenta* 2003; 24: 521-527.
- Redman CWG, Roberts JM.** Management of pre-eclampsia. *Lancet* 1993;341: 1451-1454.
- Redman CWG:** Preeclampsia the year book of obstetrics and gynecology, 8th edition 2000; P: 97.
- Rentnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B:** C-reactive protein and Gestational diabetes: The central role of maternal obesity. *J Clin Endocr Metab* 2003; 88: 3507-12.
- Ridker PM, Glynn RJ, Hennekens CH:** C-reactive protein adds to the predictive value of total and HD2 cholesterol in determining risk of first myocardial infection. *Circulation* 1998; 97: 2007.
- Ridker PM:** High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation* 2001; 103(13): 1813.
- Robert JM:** Pregnancy related hypertension. In: Creasy RK, Resink Reds. *Maternal-fetal Medicine Preinciples and practice*, endn. WB Saunders Co. 1994.

- =====
- Roberts JM and Cooper DW:** Pathogenesis and genetic of preeclampsia: Lancet 2001; 357: 53-56.
- Robillard P-Y, Hulse TC, Perianin J, Janky E, Miri EH, Papiernik E.** Association of pregnancy induced hypertension with duration of sexual co-habitation before conception. Lancet 1994; 2344: 973-975.
- Rodriguez MH, Masaki DI and Mestman J et al.:** Calcium/Creatinine ratio and Microalbuminuria in the prediction of preeclampsia. Am J Obstet Gyencol 1988; 159: 1452.
- Ross R:** Atherosclerosis an Inflammatory disease. N Eng L J Med 1999; 340(2): 115.
- Sacks GP, Syeani L, Lavery S, Trew G:** Maternal C-reactive protein levels are raised at 4 weeks gestational. Hum Reprod 2004; 19: 1025-30.
- Saijo Y, Maeda K and Nakaya Y et al.:** Altered sensitivity to a novel vasoconstrictor endothelin-1 (1-31) in myometrium and umbilical artery of women with severe preeclampsia. Biochem Biophys Res Commun 2001; 286(5): 989.
- Saito M, Ishimitsu T, Minami J, Ono H, Ohru M, Matsuoka H:** Relation of plasma high-sensitivity C-reactive protein to traditional Cardiovascular risk factor Atherosclerosis 2003; 1: 73-9.
- Sargent IL:** Maternal and fetal immune responses during pregnancy. Exp Clin Immunoglobulins 1988; 10: 85.

- =====
- Savvidou MD, Lecs CC and Parra M et al.:** Levels of C-reactive protein in pregnancy women who subsequently develop preeclampsia. *Br J Obstet Gyencol* 2002; 109(3): 297-301.
- Selahattin K, Ahmed G and Selim K et al.:** correlation of maternal serum high-sensitive C-reactive protein levels with biochemical and clinical parameters in preeclampsia. *Eur J Obstet Gynecol and Reprod Biol* 2005; 124(2): 164-167.
- Serin YS, Ozcelik B and Bapbuo M et al.:** Predictive value of Tumour Necrosis factor alpha (TNF-alpha) in preeclampsia. *Eur J Obstet Gynecol Biol* 2002; 100(2): 143.
- Shaarawy M and Abdel-Magid MA:** Plasma endothelin-1 and mean arterial pressure in prediction of preeclampsia. *Int J Gyencol Obstet* 2000; 68: 105.
- Sheehan HL:** Pathological lesion in the hypertensive toxemias of pregnancy. In: Hammond J, Browene FJ, Wolstenholem GEW (eds): *Toxemias of pregnancy, human and veterinary*. Philadelphia J Steer, Carl P Weiner, and Bernard Gonik. Hypertension. IN *High risk pregnancy: management options*, 3rd ed, USA, El Sevier 1950, p 772-797.
- Shipp TD and Wilkine HL:** The association of early onset fetal growth restriction, elevated maternal alpha fetoprotein in preeclampsia. *Prenatal Diagnosis* 1997; 17: 303.
- Sibai BM.** Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol.* 2003;102(1):181–192.
- Sibai BM.** Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. *Am J Obstet Gynecol.* 2004;190(6): 1520–1526.

- =====
- Sibai BM:** Diagnosis and management of gestational Hypertension and preeclampsia. *Obstet Gyencol* 2003; 102: 181.
- Sibai BM:** Hypertension in pregnancy and respiratory system. *Clin Obstet Gyencol* 1995; 32: 315.
- Sibai BM:** Hypertension in pregnancy. *Clin Obstet Gynecol* 1982; 35: 315.
- Sibai BM:** Treatment of hypertension in pregnant women. *N Engl J. Med* 1996; 335: 257.
- Silver RK, Turbo JM, Baried JA et al.:** Soluble factors produced by isolated 1st trimester chorionic villi directly inhibit the immune system. *Am J Obstet and Gyencol* 1990; 163: 84.
- Soloman C and Seely E:** Hypertension in pregnancy. *Endocrinol Metab Clin N Am* 2006; 35: 157-171.
- Spatling L, Spatling G.** Magnesium supplementation in pregnancy: A double blind study. *British Journal of Obstetrics and Gynaecology* 1988; 95: 120.
- Stamilio DM, Sehder HM, Morgan MA et al.:** Can antenatal clinical and biochemical markers predict the development of sever preeclampsia? *Am J Obstet Gyencol* 2000; 182: 589.
- Stubbs TM, Lazarchick J, van Porsten JP, et al.:** Evidence of accelerated platelet production and consumption in nonthrombocytopenic preeclampsia. *Am J Obstet Gyencol* 1986; 155: 263.
- Stuveling EM, BAkker SJ, Hillege HL et al.:** C-reactive protein modifies the relationship between blood pressure and microalbuminuria. *Hypertension* 2004; 4: 791-6.

- =====
- Stuveling EM, Hiillega HL, Bakker SJ, Gans RO, De Long PE, De Zeeuw D:** C-reactive protein is associated with renal function abnormalities in a nondiabetic population. *Kidney Int* 2003; 2: 654-61.
- Teren E, Escudero C and Moya W et al.:** Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. *Int J Gyencol Obstet* 2001; 5: 243-249.
- Thompson D, Pepys MB and Wood SP:** Structure of c-reactive protein 1999; 7: 169.
- Tinnakorn Chaiworapongsa, Roberto Romero, Jimmy Espinoza, Emmanuel Bujold et al.:** Evidence supporting a role for blocked of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. *A J of Obstet and Gynecology* 2004 190: 1541-50.
- Tjoa ML, van Vugt JM, Go AT, Blankenstein MA, Oudejans CB, van Wijk IJ (2003):** Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. *J Report Immunol* 2003; 59: 29-37.
- Tsatsaris V, Goffin F, Munaut, C et al.:** Overexpression of the soluble vascular endothelial growth factor receptor in pre-eclamptic patients: Pathophysiological consequences. *J Clin Endocrinol Metab* 2003; 88: 5555.
- Ustun Y, Engin-Ustun Y and Komaci M:** Association of fibrinogen and C-reactive protein with Severity of preeclampsia. *Eur J Obstet Gyencol Reprod Biol* 2005; 121(2): 154-8.

- =====
- Van Leuwen M and Van Rijswijk MH:** Acute phase proteins in monitoring inflammatory disorders *Bailliere's clinical rheumatology* 1994; 8: 531-552.
- Van Wijik M, Kublckienekm Boerk, Van Bavel E:** Vascular function in preeclampsia *Cardiovascular Res*; 2000; 1: 38.
- Von Dadelszen P, Magee LA.** Antihypertensive medications in management of gestational hypertension-preeclampsia. *Clin Obstet Gynecol.* 2005;8(2):441–459.
- Waisman GP, Mayorga LM, Camera MI, Vignolo CA, Martinotti A.** magnesium plus nifedipine: potentiation of hypotensive effect in pre-eclampsia. *American Journal of Obstetrics and Gynecology* 1988; 159: 308-309.
- Walf M and Thadhani R:** First trimester C-reactive protein and subsequent gestational diabetes. *Diabetes Car* 2003; 26: 819-824.
- Walf M, Kettyle E, Sandler L, Ecker JL, Roberts J and Ihadhani RC:** Obesity and preeclampsia: The potential role of inflammation. *Obstet Gyencol* 2001; 98: 7857-762.
- Walker JJ:** Advances in the management of sever preeclampsia and antihypertensive therapy. In: Bonnar J (ed): *Recent Advances in Obstetrics and Gynecology.* London, Churchill Livingstone 1998; 3: 805-815.
- Walsh SC:** Lipid peroxidation in pregnancy. *Hypertens Preg* 1994; 13: 1.
- Wang Y, Gu Y, Zhang Y Lewis DF:** Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell

- permeability in endothelial cells from preeclampsia, Am J Obstet Gynecol 2004; 3: 817.
- Wilson BJ, Watson MS, Prescott GJ et al.:** Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from Cohort Study. BMJ 2003; 326: 845.
- Witlin AG, Sibai BM:** Diagnosis and management of women with haemolysis elevated Liver enzymes and low platelets count (HELLP) syndrome. Hosp Physician 1999; 40: 49.
- Woods DL, Molar AF.** Side effects of labetalol in new born infants. British Journal of Obstetrics and Gynaecology 1983; 90: 876.
- Xiang X, Demianczuk N-N and Saunders CD et al.:** Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2000; 155: 203.
- Yoneyama Y, Suzuki S, Sawa R, Yoneyama K, Power GG, and Araki T:** Relation between adenosine and T-helper 1/T helper 2 imbalance in women with preeclampsia. Obstet Gynecol 2002; 99: 641-6.
- Yoon BH, Jun JK, Park KH, Syn HC, Gomez Rand Romero R:** Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. Obstet Gyencol 1996; 88: 1034-1040.
- Young B, Glesson M, Cripps, AW:** C reactive protein: A critical review. Pathology 1991, 23: 118.
- Yudkin, JS, et al.:** C-reactive protein in healthy subjects: Association with obesity, Insulin resistance and endothelial dysfunction. A potential role for cytokines originating from